SCHEDULE 13G/A: Schonfeld Strategic Advisors Discloses 6.16% Stake in Terns Pharmaceuticals

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 6.16% in Terns Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Schonfeld Strategic Advisors LLC reported beneficial ownership of 5,234,508 shares of Terns Pharmaceuticals, Inc. common stock.
• This represents 6.16% of Terns Pharmaceuticals' outstanding common stock.
• The percentage is based on 84,938,855 shares outstanding as of November 8, 2024, as reported in Terns Pharmaceuticals' Form 10-Q filed on November 12, 2024.
• Schonfeld Strategic Advisors LLC acts as an investment adviser to several private funds and engages third-party sub-advisers.
• The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral, factual disclosure.

Positives

• The disclosure of a significant institutional holding by Schonfeld Strategic Advisors LLC may signal confidence from a notable investment firm in Terns Pharmaceuticals, Inc.
• The investment is stated to be in the ordinary course of business, indicating a passive investment rather than an activist stance that could create uncertainty.

Future Outlook

The Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Terns Pharmaceuticals, Inc.'s future performance or strategic outlook.

Management Comments

• Schonfeld declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934 or any other purpose, the beneficial owner of any securities covered by this statement.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing is a standard disclosure in the financial industry, where institutional investors like Schonfeld Strategic Advisors are required to report significant ownership stakes (over 5%) in publicly traded companies. Such filings provide transparency into major shareholder positions, which can be of interest to other investors tracking institutional sentiment and potential long-term holdings in the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may be viewed positively, potentially signaling confidence in the company's long-term prospects.
• Management: Awareness of a large institutional holder may influence management's strategic considerations, though Schonfeld states its investment is passive.

Key Dates

Keywords

Terns Pharmaceuticals, Schonfeld Strategic Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Investment Advisor, SEC Filing, Biotechnology, Pharmaceuticals